Good morning ladies and gentlemen. Thank you for standing by. Welcome to the Milestone Scientific Second Quarter 2022 Business Update Call. At this time, all participants are on a listen only mode. After management's prepared remarks, there will be a question and answer session. I would now like to turn the call over to David Waldman, Investor Relations. Please go ahead. Good morning and thank you for joining Milestone Scientific second quarter 2022 financial results conference call. On the call with us today are Arjan Haverhals, Chief Executive Officer, and Keisha Harcum, Controller of Milestone Scientific. The company issued a press release today containing second quarter 2022 financial results, which is also posted on the company's website. If you have any questions after the call or would like any additional information about the company, please contact Crescendo Communications at 212-671-1020. Company's management will now provide prepared remarks reviewing the financial and operational results for the second quarter June 30th, 2022. Before we get started, we'd like to remind everyone that during this conference call we may make forward-looking statements regarding timing and financial impact, Milestone's ability to implement its business plan, expected revenues, and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive, and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including, without limitation, Milestone's report on Form 10-K for the year ended December 31st, 2021, and Milestone's report on Form 10-Q for the second quarter June 30th, 2022. The forward-looking statements made during this call are based on management's reasonable belief as of today's date, August 16th, 2022. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. With that, we'll now turn the call over to Arjan Haverhals, Chief Executive Officer. Please go ahead, Arjan. Thank you David and thanks to everyone for joining us today. I'd like to start our discussion this morning by discussing the results within our dental segment and then take a moment to share some of the exciting developments within our medical segment. As we shared in our press release this morning, I'd like to highlight that U.S. sales within our dental segment were relatively unchanged, which is noteworthy considering we had very significant orders from Henry Schein last year as they built up their inventory as dental offices were reopening. On the international front, we did not record any sales from our China distributor in the second quarter of 2022. Specifically, we have run into challenges dealing with them as well as doing business in China. Outside of China, our international sales would have been consistent with last year had it not been for cancellation of orders in Russia and Ukraine. Importantly, we continue to add third-party dental distributors in other international markets. As an example, we recently granted Hager & Werken exclusive distribution rights to market Milestone's STA Single Tooth Anesthesia System in Germany and Austria. Hager & Werken brings a proven track record introducing dental instruments in these two markets, which have a combined population in excess of 90 million people. We look forward to announcing additional international distribution agreements as we continue to build our network across Asia, Africa, South America, and Europe. In the U.S. we're also looking to bring on new strategic channel partners that sell through their network of dental customers especially in specialized areas of dentistry, such as implant dentistry anesthetics, as well as large dental groups, also known as dental service organizations or DSOs, reflected in the distribution agreements we announced earlier this year. Overall, our dental business remains strong, and we remain encouraged by the outlook for the business going forward. Turning to our medical segment, we have made significant progress rolling out our CompuFlo Epidural System across a number of important hospitals, healthcare systems, and pain management clinics. Just last month, we were approved as a vendor within a leading medical center in Southern California, serving over 10 million members with more than 100,000 babies delivered each year across multiple states. This healthcare system was designated as having one of the best maternity care hospitals by Newsweek. Our selection by this leading medical center followed a thorough trial and evaluation which further validates the safety and efficacy of our technology. With each health system we sign, we benefit not only from the sales but also growing validation within the market. In turn, this potentially helps shorten the sales cycle for subsequent hospitals and pain management clinics. In addition to our growing regional presence, especially in Florida, Texas, and the New York tri-state area, we're also targeting tier one university teaching hospitals. As I've mentioned in the past, several of these hospitals are among the top 20 in the nation. As we begin to penetrate some of these larger, well-recognized names, it will continue to add credibility and validation to the instrument, which we hope will create a snowball effect. We also continue to launch our CompuFlo Epidural System within pain clinics across the U.S. With over 11 million reported epidural procedures each year, the pain management market is at least twice the size of the labor and delivery market segment. The pain management market not only includes numerous hospitals, but also specialty centers, outpatient centers, and sports medicine centers. Shifting gears, it was an honor to have our CompuFlo Epidural System incorporated into the student registered nurse anesthetist or SRNA program at the University of Scranton. According to the U.S. Bureau of Labor Statistics, nurse anesthetists already outnumber anesthesiologists in the U.S., and every year, more nurse anesthetists are entering the field and playing an increasingly important role in anesthesia. For this reason, having our instrument integrated into the curriculum is not just an important validation, but key to our long-term commercial strategy. Another major accomplishment this quarter was the receipt of a CPT code from the American Medical Association for the CompuFlo Epidural System. I cannot overstate the importance of having our own CPT code, which has the potential to open new doors by enhancing potential reimbursement. With the CPT code now in hand, we're seeing increased traction with potential customers. As an example, we expect to announce shortly another major health system that operates six hospitals and four medical centers, providing patient care to more than 1.5 million patients each year. We expect this institution will immediately begin implementing CompuFlo across three distinct departments, the operating rooms, labor and delivery, as well as acute pain. We look forward to providing an update on this institution in the days ahead. In addition to our direct sales channels, we are also expanding our network of distribution partners. We recently re-engaged with our U.S. distribution partner, Clinical Technology Incorporated, also known as CTI, and added a new international distributor in Greece. CTI is a leading specialty distributor of medical products in the Midwest and East Coast regions of the United States. Although we initially started our collaboration with CTI in 2018, we mutually agreed to delay the launch based on customer feedback in 2018. Specifically, we agreed it would be helpful to have the economic benefit analysis in hand, as well as initial adoption by key referenceable hospitals. We accomplished both of those goals, including the addition of key referenceable hospitals, healthcare systems, and pain management clinics, as well as publication of the economic benefit analysis, which demonstrated real-time pressure sensing technology, our technology, reduces cost by about $504 per average patient hospital stay. Equally important to them was the issuance of our new CPT code, which I mentioned a moment ago. We are actively preparing a full launch plan in anticipation of this new AMA-cleared CPT code that will be implemented in the first quarter of 2023. On the heels of receiving the CPT code, we immediately re-engaged our partnership with CTI, which illustrates the significant progress we have achieved over the past years. CTI is an ideal partner, bringing a sizable Midwest and East Coast sales force, extensive relationships with physicians, pain clinics, and hospitals, as well as a proven track record of introducing new medical devices. In Greece, our new partner, F&M Feid, is a leading provider of medical equipment, devices, and consumables. They bring over 40 years of experience in the field of healthcare, having a successful track record launching new medical devices and equipment. We believe that Greece is another important market for us, with a population in excess of 10 million people and 76,000 childbirths each year. We look forward to announcing additional international distributors as we advance our commercial rollout. As you can see, we make significant progress for the medical segment. Let me now take a moment to discuss some important financial initiatives that we have undertaken. First, we have reallocated additional resources towards our medical segment, which we believe represents the future of the company. We expect our dental business will continue to grow and now have a solid distribution network and marketing support in place to cost-effectively scale the business. On the other hand, our medical segment represents a much larger addressable market, not only driven by cost and convenience for the provider, but driven by the safety considerations, cost savings, and the ability to have remuneration given the success of obtaining the CPT code, which we believe will ultimately lead to the CompuFlo becoming standard of care. In the meantime, we have significantly reduced our operating expenses and corporate overhead by nearly $700,000 in the second quarter. We are also implementing additional cost reductions beginning in the third quarter of 2022, which we believe will be reflected in our financial results in the coming quarters. As a result of these initiatives, we are implementing a much leaner cost structure that should drive operating efficiency and improve profitability as we continue to grow revenues. Combine that with our disposables, which provide high margin recurring revenue, we believe we are well-positioned to drive shareholder value for years to come. We also ended the quarter with approximately $11 million of cash on hand and no long-term debt, which provides us sufficient capital to continue executing our business strategy. To summarize, we have positioned our company for positive growth in the coming quarters. We remain committed to our goal of establishing the CompuFlo epidural instrument as the new standard of care in epidural anesthesia by providing patients with effective pain relief while reducing the risk of complications. Given recent developments, including the addition of new hospitals, expanded distribution, the new CPT code, and our streamlined operating structure, we believe the future is bright. At this point, I'd like to turn the call over to Keisha Harcum, Controller, to go over the financials in detail. Please go ahead, Keisha. Thank you Arjan. Consolidated revenue for the three months June 30th, 2022 and 2021 was approximately $1.6 million and $2.4 million, respectively. Dental revenue decreased approximately $795, 000 for the three months June 30th, 2022, as compared to the three months June 30th, 2021. For the three months June 30th, 2022, dental domestic revenue decreased approximately $21, 000 and dental international revenue decreased approximately $248, 000 compared June 30th, 2021. For the three months June 30th, 2022, the company recorded no revenue from China as compared to approximately $525, 000 for the three months June 30th, 2021. Medical revenue increased approximately $17,000 for the three months June 30th, 2022, as compared to the three months June 30th, 2021. Consolidated gross profit for each of the three months June 30th, 2022 and 2021 decreased approximately $689,000 or 41% versus $1.4 million or 56% of revenue for the second quarter of 2021. The decrease is related to the company recording an allowance of approximately $430,000 on slow-moving medical finished goods during the three months June 30th, 2022. Consolidated selling general and administrative expenses for the three months June 30th, 2022 and 2021 were approximately $3.3 million and $4 million, respectively. The decrease of approximately $729,000 is categorized in several ways. Consolidated research and development expense for the three months June 30th, 2022 and 2021 was approximately $267,000 and $215,000, respectively. The increase of approximately $51,000 is related to the company exploring enhancements on the STA Single Tooth Anesthesia System product. The loss from operations was approximately $2.9 million for the three months ending June 30th, 2022 and 2021, respectively. Consolidated revenue for the six months ending June 30th, 2022 and 2021 was approximately $4.3 million and $5.4 million, respectively. Dental revenue decreased approximately $1 million for the six months ending June 30th, 2022 as compared to the six months ending June 30th, 2021. For the six months ending June 30th, dental domestic revenue decreased $67,000, and dental international revenue decreased approximately $216,000 compared to June 30th, 2021. For the six months ending June 30th, the company revenue to China decreased approximately $672,000 compared to June 30th, 2021. Medical revenue decreased approximately $46,000 for the six months ending June 30th, 2022, as compared to the six months ending June 30th, 2021. Consolidated gross profit for each of the six months ending June 30th, 2022 and 2021 decreased $809,000, 25%. The decrease is related to the company recorded allowance of approximately $430,000 on slow-moving finished goods for medical and the reduction of dental revenue. Consolidated selling, general, and administrative expense for the six months ending June 30th, 2022 and 2021 were approximately $6.4 million and $6.8 million, respectively. The decrease of approximately $363,000 is categorized in several areas. Consolidated research and development expenses for the six months ending June 30th, 2022 and 2021 was approximately $731,000 and $231,000 respectively. The increase of approximately $499,000 is related to the company continuing enhancement of the STA Single Tooth Anesthesia System product. The loss from operation was approximately $4.8 million and $3.9 million for the six months ending June 30th, 2022 and 2021 respectively. As of June 30th, 2022, the company has incurred net losses of approximately $2.9 million or loss of $0.04 per share for the three months ending June 30th, 2022 versus a net loss of $2.7 million or $0.04 per share for the comparable period in 2021. As of June 30th, the company has incurred a net loss of $4.8 million loss or $0.07 per share for the six months ending June 30th, 2022 versus net loss of $3.7 million or $0.055 per share for the comparable period in 2021. On June 30th, 2022, Milestone Scientific had cash and cash equivalents of approximately $11 million and working capital of $12.3 million versus working capital of $15.8 million on December 31st, 2021. For the six months ending June 30th, 2022 and 2021, we had cash flows used in operating activities of approximately $3.8 million and $2.1 million respectively. At this point, I would like to turn the call back over to Arjan Haverhals. Thank you Keisha. To wrap up, we believe we have developed a cost-effective and highly scalable platform to drive growth within both our dental and medical divisions. We are witnessing growing interest in both our instruments and our disposables, and we believe we are well-positioned to take advantage of the opportunities available in the market. I'd like to thank you for joining the call today, and at this point we would like to open the call up to questions. Operator. Certainly. The floor is now open for questions. If you have any questions or comments, please press star one on your phone at this time. We ask that while posing your question, you please pick up your handset if listening on a speakerphone to provide optimum sound quality. Please hold one moment while we pull for questions. Your first question is coming from Anthony Vendetti at Maxim Group. Please pose your question. Your line is live. Thank you. Arjan, just wanna understand that, you know, the dental business, obviously some of the stuff out of your control with the, you know, ongoing war in Ukraine and it sounds like you had Russian and Ukraine customers that canceled orders, which totally makes sense. What's the magnitude of the business that you were doing in Russia and Ukraine prior to Russia's invasion? Yes. Thank you Anthony and good morning. First of all, you know, the results in the dental division are, of course, disappointing. On one hand, you know, we can say it is out of our control because the situation in China and the situation in Russia and Ukraine. I can share with you the magnitude of the business impact that we had in the H1 of the year with Russia and the Ukraine, which was the magnitude of about $300,000 combined that we could not deliver. On top of that, of course, the company has taken the position that we, based on the war, do not want to do any business with Russia. Okay. Absolutely. That makes sense. China, I know, has been lumpy in terms of some quarters, you get a fairly large order, other quarters, like this quarter, there's no order. You also mentioned that it's getting more difficult to do business in China as well. Does that mean that you're not expecting future orders from China or it's just less predictable? Yeah. I think the honest answer here, Anthony, is we don't know, because to your point, it is less predictable. On one hand, you have of course also the economic and governmental situation in China. We know, you know, the real estate market, the GDP development in China, is not in favor for the business, as well as what we reported in the 10-K and also in the first quarter this year, that we have some challenges with the Chinese distributor. It is very difficult to predict what that effect will be. We are investigating, you know, the position towards China and the distributor. We have decided that for the time being, we are not going to undertake any actions because of the situation in China, because of the cost involved. That's, you know, has been concluded for us that we take a wait and see approach. To that point, it is extremely difficult to predict what and when and if we would get additional revenues within this year on the China business. Okay. Shifting gears, just wanna ask a couple questions on the medical side. You know, noticed throughout the quarter, obviously, you've signed up. Oh, some nice universities, hospitals that, you know, hopefully help drive the disposable component of the CompuFlo system. Can you talk about where we are in terms of hitting an inflection point, at least in your judgment, where you'll start to derive material revenue from the medical side? Yeah. I think there are three important factors, right? If we go to the hospitals where we are currently active, we are in a number of hospitals active in a trial and evaluation situation. As you know, in labor and delivery, that sales cycle is rather, let's say, longer compared to the pain segment. Nevertheless, we continue to penetrate these hospitals, and I'm very pleased with the activity level that we are having based in these hospitals. In light of that, it's also very important that we have access to a distribution partner, which is CTI, because they are covered in about 22 states in the United States, so they have a very large footprint. That's the labor and delivery market segment. I think that the turning point or the reflection point, not only from the hospitals, but also more importantly from the private pain clinics, and the ASCs, is all very much so dependent on, getting the reimbursement pricing for the CPT code ready. As I mentioned in the call this morning, the preparation of the launch for that CPT code is of utmost importance for the company moving forward. Not only because of the addressable market size, the pain segment is about 2-3 x the labor and delivery market segment, but also, more importantly, the shorter sales cycle. All the work that we put in the medical segment is staying laser-focused on those territories and geographical areas where we are already active, as well as preparing for the CPT code. Thirdly, also looking into other channel partner opportunities, where we, you know, get access to other organizations and institutions, thereby driving penetration and adoption of our medical technology. Just the last follow-up on the CPT code. Typically, there's a comment period, and then the code goes into effect each year on January 1st, January 2nd, whichever the case. Are you confident that the starting in January of 2023, that you'll have a new code that's approved by CMS? Okay. Let me explain it, if I understand your question correctly, Anthony. We have been granted a CPT Category III code, which becomes effective as of January 1st, January 2nd, next year 2023. What we have to do then is in the extension to that, and that's where we are working and preparing for right now, is instead of waiting till January and February and then getting access to insurance companies and getting a price or a reimbursement for the pain clinics, we are trying to set that up right now. The first part of your question, the code, it's already confirmed that we will get that in January 2023. We are preparing, you know, well in advance, to be even more ready in the first quarter of next year because we strongly believe that we will sort hopefully the effect of that CPT code during the first quarter of 2023. Okay, great. That was helpful. Thanks Arjan. I'll hop back in the queue. Thank you Anthony. Once again, if there are any remaining questions or comments, please press star one on your phone at this time. Your next question is coming from John Corb. Please pose your question. Your line is live. Arjan? Yes. Good morning J ohn. Hello. Hi, Arjan. John Corb. I'm a longtime shareholder. I've talked with you before. Yes. First of all, I want to share with you that this summer, I was the recipient of the STA technology with my dentist, and it's everything Milestone has ever claimed. It is totally painless injection. That dentist loves it. I love it. Begs the question, you know, how does it wide-scale in use? The dental business has been long time part of. I didn't ask my dentist, but I assume he got this through a distributorship. I'm more interested, maybe I shouldn't be, but I'm more interested in what's going on in the United States. Mm-hmm. Versus other countries with the dental. Are you still hopeful that instead of muddling along with ups and downs, you know, just down this quarter because we're comparing with Henry Schein uploading, and then we lose China, and then we gain this, to get traction in the dental area, is that still a hope and a plan for Milestone Scientific? Yes, thank you for your question J ohn and I'm very pleased that you had the experience that that many other patients had with our STA, Single Tooth Anesthesia Technology. Let me answer your question. You're absolutely right. Yes, we are focusing as a company on further growing the dental business in the United States. To your point, not being only dependent on a distributorship with Henry Schein. As we started with in the beginning of last year, we added a number of other distributors. We went from an exclusive distributorship with Henry Schein to a multi-channel or a multi-distribution sales channel. Now, you know, was that enough to achieve the growth that we would like to see for the company? We came to the conclusion that is not necessarily enough, and we have to do more. Have to do more meant then at that time, that we looked into other, what I call channel partners. A very good example is Keystone Dental Group, which is a dental implant company, having a sales force of about 75 people, and only carry, let's say, a dental implant and some of the prosthetic components in their portfolio. Having then the opportunity to also offer our product and technology, giving them the opportunity to increase their business and increase their penetration in the general practitioner market segment, without having an erosion of their, call it, their profit margins on their core business, was a very attractive value proposition, and they jumped on to it. That's another important factor that we continue to look at and to identify those channel partners, as for example, Keystone Dental Group. What's even more important, I think from a growth perspective point of view, is the development of the dental service organizations, not only in the United States as well as in Europe, but let's go back to the United States. I think currently about 22% of all the dental business is done through these dental service organizations. They have a central purchasing administration services, insurance, health, private health insurances that they offer to their patients. Getting access to that DSO market segment is of utmost importance. That's culminated in us signing up an agreement with a dental service organization called AIDA in the beginning of this year. As we speak, we are continuing in an accelerated approach to get in front of the dental service organizations and then in particular with the C-suite, so the CEO, the COO, the CMOs of these dental service organizations. Because we have a fantastic value proposition for the DSOs to increase their revenues dramatically and drastically, as we are able to document and demonstrate based on literature that they can increase their patient acceptance. Now, I know it's a little bit a long answer to your question, but in short, you know, it's not for me coming out of the valley and closing the gap. It's for me, more important and for the company, more important to focus on sustainable growth for the dental business in the United States moving forward. Okay. Thank you for that answer. Moving on to CompuFlo. Yeah. I haven't been up to speed, but you know, I'm reminded of the initial thrust with Milestone and the CompuFlo. As I recall, you hired 10 salesmen and going to focus east of the Mississippi River. When you made that statement, we have 10 capable sales force on hand, that they were going nowhere without the CPT code. I didn't even know there was such a thing as a CPT code. And then the CTI relationship, I was not aware that wasn't going anywhere with the CPT code. Hello. Excuse me. Can everybody hear me? Hello? I can hear you. Okay. John. I didn't hear the second part of John's question. I think I've lost John. Yes, I think. Yeah, I think we lost him. You can go ahead and address the first part. Yeah. I think the Commodore, the question was, 10 sales reps are not necessarily being aware of the CPT code or the importance of the CPT code and the relationship with CTI. I will keep it short. The relationship with CTI, as we stated, there was a relationship in 2018, but that was also at the time where the company decided to improve and to optimize the product at that time based on some customer feedback and also in parallel with that to conduct an independent study to search for the health economic benefits of our technology and our system, which then resulted in the $504 cost saving per average patient hospital stay. The question on the 10 sales representatives, as we also have mentioned in the 10-Q, we have reduced the medical sales team in half. We have a sales team of five dedicated people on the ground, which is a result of, you know, being laser-focused and focusing on those areas where we have the best and the best leads, so to say, and the highest activities, in the hospitals in those territories. The reason why we also want to go for a hybrid model is, of course, that through CTI, you get a geographical coverage and spread much higher than we can do on our own, as well as, you know, the cost efficiencies. Because having a direct sales organization of 10, 20 or 30 people is a tremendous cost, on our balance sheet and, therefore, we also decided to be re-engaged with CTI. Thank you. There appear to be no further questions in the queue at this time. I would now like to turn the floor back over to management for any closing remarks. Yes. Well, again, thank you for your time. As I've stated before, we remain positive about and encouraged about the developments that we have seen and that we are focusing on in both the medical segment. We're working hard, also, and we believe also that we have the strategic plan identified to further substantiate on the dental business. We remain encouraged and positive about the company moving forward and continue to create shareholder value. I will thank you again for your time. Stay safe and looking forward to either meet with you or speak to you in the near future. All the best. Thank you, ladies and gentlemen. This does conclude today's conference call. You may disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.